+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Pain Management Therapeutics Market by Drug Class, Route Of Administration, Indication, Distribution Channel, End User - Global Forecast to 2030- Product Image
Pain Management Therapeutics Market by Drug Class, Route Of Administration, Indication, Distribution Channel, End User - Global Forecast to 2030- Product Image
Sale

Pain Management Therapeutics Market by Drug Class, Route Of Administration, Indication, Distribution Channel, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 182 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4896709
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Pain Management Therapeutics Market grew from USD 86.51 billion in 2024 to USD 90.67 billion in 2025. It is expected to continue growing at a CAGR of 4.76%, reaching USD 114.41 billion by 2030.

Setting the Stage for a New Era in Pain Management

The global landscape of pain management therapeutics stands at a pivotal juncture characterized by heightened patient expectations, technological breakthroughs, and evolving regulatory frameworks. Against the backdrop of an aging population and a growing prevalence of chronic conditions, decision-makers must navigate a complex web of factors influencing drug development, market access, and patient outcomes. Advances in molecular biology, imaging modalities, and digital health platforms are converging to redefine traditional paradigms of analgesia, while mounting pressures to balance efficacy, safety, and cost continue to shape therapeutic portfolios.

This executive summary distills the most salient trends, policy shifts, and competitive dynamics reshaping the sector. Drawing on robust research methodologies and expert perspectives, the following sections chart a comprehensive view of how innovation pipelines, tariff revisions, segmentation nuances, regional variances, and leading company strategies intersect to create both challenges and opportunities. By framing these insights within a clear strategic context, industry leaders will gain the analytical foundation needed to align R&D, commercial investments, and stakeholder engagement for the next phase of market evolution.

Unprecedented Shifts Redefining Therapeutic Approaches

Over the past decade, transformative forces have redefined the contours of pain management, ushering in a shift from broad-spectrum analgesics toward targeted, personalized interventions. Precision medicine initiatives now harness genomic profiling to tailor treatments for neuropathic pain, while digital therapeutics and mobile health applications deliver real-time monitoring and adaptive dosing. Regulatory agencies are increasingly receptive to novel modalities, granting expedited pathways for non-opioid therapies and devices that demonstrate significant reductions in opioid reliance.

Simultaneously, patient advocacy groups have amplified calls for more transparent pricing models and holistic care approaches that integrate physical therapy, psychosocial support, and complementary therapies. The convergence of these trends is driving pharmaceutical and device manufacturers to forge cross-sector partnerships, invest in next-generation delivery systems, and prioritize post-market evidence generation. As a result, the market is witnessing an unprecedented wave of innovation that challenges established players to reimagine product portfolios, engage stakeholders more proactively, and embrace a truly multidisciplinary model of care.

Assessing the Ripple Effects of 2025 Tariff Revisions

In 2025, revisions to United States tariff schedules introduced new import duties on a range of active pharmaceutical ingredients and specialized excipients critical to pain therapeutics. As manufacturers absorbed higher raw material costs, supply chains became subject to increased volatility, prompting cost-containment measures and strategic stockpiling. Concurrently, domestic producers gained a modest pricing advantage, incentivizing onshore capacity expansions but also escalating competitive pressure on global exporters.

These tariff adjustments have had a pronounced effect on clinical trial supply logistics, with study sponsors reallocating sourcing strategies to mitigate delays and maintain patient enrollment targets. Moreover, adjustments to intercompany transfer pricing have emerged as a focal point for tax compliance and profit-shift planning. As companies adapt, many are exploring long-term supplier agreements, expanding regional manufacturing hubs, and leveraging digital procurement tools to optimize inventory management. In turn, payers and providers are recalibrating formulary negotiations to reflect evolving cost structures, underscoring the imperative for transparent cost-effectiveness data and agile commercial models.

Unveiling Detailed Insights Across Key Market Segments

A nuanced understanding of market segmentation reveals critical paths for targeted growth and portfolio optimization. Within the drug class dimension, adjuvant analgesics and local anesthetics continue to anchor the perioperative setting, while neuropathic pain agents-encompassing anticonvulsants and antidepressants-demonstrate steady uptake in chronic neuropathy indications. Nonsteroidal anti-inflammatory drugs maintain broad utility, yet the emergence of selective Cox-2 inhibitors and advances in traditional NSAID formulations are reshaping prescribing patterns. In parallel, opioids remain integral for severe acute and cancer pain, with strong and weak opioid categories navigating intensified scrutiny over risk-benefit profiles.

Examining routes of administration underscores shifting preferences toward patient convenience and adherence. Oral dosing retains its dominance for chronic regimens, while injectable options spanning intramuscular, intravenous, and subcutaneous routes support acute care and inpatient settings. Growing interest in transdermal and topical systems reflects the demand for localized, noninvasive delivery.

On the basis of indication, the acute pain segment is driven by surgical volume and trauma care, whereas cancer pain management benefits from integrated palliative care frameworks. Chronic pain remains the largest therapeutic area, with low back pain, neuropathic chronic pain, osteoarthritis, and rheumatoid arthritis each exhibiting unique clinical and economic drivers. Inflammatory and neuropathic pain subcategories further inform clinical trial design, labeling strategies, and market access considerations.

Distribution channel analysis highlights the critical role of hospital pharmacies in securing early pipeline adoption, alongside the rapid growth of online pharmacies that cater to telehealth-enabled prescribing. Retail pharmacy channels, whether chain or independent, are adapting to incorporate digital loyalty platforms and specialty drug services. Finally, end user segmentation reveals that ambulatory surgical centers lead in procedural volume, while home care settings-ranging from hospice care to patient residences-demand robust remote monitoring solutions. Hospitals, both private and public, continue to emphasize integrated pain pathways across inpatient and outpatient care continuums.

Divergent Regional Dynamics Shaping Global Therapeutics

Regional dynamics exert a profound influence on market trajectories, driven by heterogeneous regulatory environments, healthcare infrastructure, and disease prevalence patterns. In the Americas, emphasis on value-based care and reimbursement reforms has accelerated adoption of multimodal pain protocols, with the United States leading in digital therapeutics integration and Canada prioritizing evidence-based formulary decision-making.

Within Europe, Middle East & Africa, regulatory harmonization under the European Medicines Agency coexists with country-specific pricing negotiations, while emerging markets in the Gulf Cooperation Council and North Africa pursue localized manufacturing partnerships to bolster supply resilience. Concurrently, cost containment pressures in Western Europe are catalyzing interest in biosimilar analgesics and generic alternatives.

The Asia-Pacific region presents a tapestry of high-growth opportunities underpinned by rapidly aging populations and expanding middle-class healthcare access. Market liberalization in China and India is stimulating both domestic innovation and international collaboration, whereas Japan and Australia maintain stringent safety evaluations that encourage novel delivery systems. Across the region, public-private partnerships are shaping pain management infrastructure, from community clinics to tertiary care centers.

Strategic Moves by Leading Industry Innovators

Market leadership is increasingly defined by the strategic portfolios and collaborative initiatives of major pharmaceutical and biotechnology firms. Global players such as Pfizer and Johnson & Johnson continue to refine their analgesic pipelines through targeted acquisitions and partnerships, integrating small molecules with device-enabled delivery platforms. AbbVie’s focus on next-generation JAK inhibitors and Eli Lilly’s investment in anti-NGF antibodies illustrate the push toward mechanism-based therapies with differentiated safety profiles.

At the same time, specialty companies such as Grünenthal and Mallinckrodt pursue niche opportunities in neuropathic pain and interventional analgesia, leveraging clinical data to secure orphan drug designations and formulary access. Generic and biosimilar producers, including Teva and Mylan, intensify competition in established segments, driving margin pressures but also expanding patient affordability. Digital health collaborations between traditional manufacturers and health technology firms are gaining momentum, exemplified by joint ventures that embed mobile monitoring into post-operative care. These collective efforts underscore an ecosystem in which innovation, scale, and agility determine sustainable competitive advantage.

Actionable Imperatives to Drive Future Growth

To thrive amid accelerating change, industry leaders should prioritize a multi-pronged strategy centered on innovation, agility, and stakeholder alignment. First, diversifying supply chains through dual-sourcing agreements and regional manufacturing hubs will mitigate tariff-related risks and ensure continuity in clinical and commercial supplies. Second, embedding digital health tools within development programs and post-market surveillance can enhance patient adherence and generate real-world evidence to support value propositions.

Third, forging public-private partnerships and engaging payers early in clinical trial design will facilitate coverage decisions and reimbursement pathways, especially for high-cost, mechanism-based therapies. Fourth, aligning R&D investments with precision medicine trends-such as genetic biomarkers for neuropathic pain-will differentiate portfolios and unlock premium pricing. Finally, adopting sustainable pricing models that reflect both clinical benefit and economic impact will strengthen payer relationships and support long-term revenue growth. By implementing these imperatives, organizations can convert market insights into actionable growth engines and resilient commercial frameworks.

Rigorous Methodological Framework Underpinning Insights

The insights presented in this report derive from a rigorous, multi-phase research methodology designed to ensure accuracy, relevance, and strategic impact. Primary research included in-depth interviews with over 50 industry experts, comprising senior executives from pharma and biotech firms, key opinion leaders in pain management, and senior representatives from payers and regulatory bodies. Complementary secondary research encompassed peer-reviewed journals, clinical trial registries, regulatory filings, and proprietary trade databases.

Market segmentation and sizing analyses were validated through cross-reference of supply-side data and demand-side indicators, while tariff impact assessments leveraged harmonized trade classification systems and government publications. Data triangulation techniques ensured consistency across sources, and quantitative findings were stress-tested alongside qualitative insights to identify emerging risks and opportunities. This methodological framework underpins the robustness of our conclusions and delivers a structured foundation for strategic planning and decision-making.

Converging Trends Forge the Future of Pain Therapeutics

The convergence of technological innovation, policy evolution, and patient-centric care models is forging a new paradigm in pain management therapeutics. Multi-modal approaches are displacing one-size-fits-all strategies, encouraging stakeholders to embrace personalization, digital integration, and evidence-driven value arguments. Regional disparities and tariff shifts further underscore the necessity of adaptive supply chains and pricing frameworks, while segmentation granularity illuminates targeted growth avenues across drug classes, delivery routes, indications, channels, and end-user settings.

As leading companies craft strategic alliances and refine their pipelines, the ability to anticipate market dynamics and pivot swiftly will determine market leadership. The actionable recommendations and comprehensive insights outlined here offer a blueprint for organizations seeking to navigate complexity, capitalize on innovation, and deliver superior patient outcomes. By synthesizing rigorous analysis with practical guidance, this executive summary equips decision-makers to chart a clear path forward in an increasingly competitive environment.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Drug Class
    • Adjuvant Analgesics
    • Local Anesthetics
    • Neuropathic Pain Agents
      • Anticonvulsants
      • Antidepressants
    • Nonsteroidal Anti-Inflammatory Drugs
      • Cox-2 Inhibitors
      • Traditional NsaiDs
    • Opioids
      • Strong Opioids
      • Weak Opioids
  • Route Of Administration
    • Oral
    • Parenteral
      • Intramuscular
      • Intravenous
      • Subcutaneous
    • Topical
    • Transdermal
  • Indication
    • Acute Pain
    • Cancer Pain
    • Chronic Pain
      • Low Back Pain
      • Neuropathic Chronic Pain
      • Osteoarthritis
      • Rheumatoid Arthritis
    • Inflammatory Pain
    • Neuropathic Pain
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
      • Chain Pharmacy
      • Independent Pharmacy
  • End User
    • Ambulatory Surgical Centers
    • Home Care Settings
      • Hospice Care
      • Patient Home
    • Hospitals
      • Private Hospitals
      • Public Hospitals
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Johnson & Johnson
  • Pfizer Inc.
  • Novartis AG
  • Bayer AG
  • GlaxoSmithKline plc
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Endo International plc
  • Mallinckrodt plc
  • AstraZeneca plc

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Pain Management Therapeutics Market, by Drug Class
8.1. Introduction
8.2. Adjuvant Analgesics
8.3. Local Anesthetics
8.4. Neuropathic Pain Agents
8.4.1. Anticonvulsants
8.4.2. Antidepressants
8.5. Nonsteroidal Anti-Inflammatory Drugs
8.5.1. Cox-2 Inhibitors
8.5.2. Traditional NsaiDs
8.6. Opioids
8.6.1. Strong Opioids
8.6.2. Weak Opioids
9. Pain Management Therapeutics Market, by Route Of Administration
9.1. Introduction
9.2. Oral
9.3. Parenteral
9.3.1. Intramuscular
9.3.2. Intravenous
9.3.3. Subcutaneous
9.4. Topical
9.5. Transdermal
10. Pain Management Therapeutics Market, by Indication
10.1. Introduction
10.2. Acute Pain
10.3. Cancer Pain
10.4. Chronic Pain
10.4.1. Low Back Pain
10.4.2. Neuropathic Chronic Pain
10.4.3. Osteoarthritis
10.4.4. Rheumatoid Arthritis
10.5. Inflammatory Pain
10.6. Neuropathic Pain
11. Pain Management Therapeutics Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
11.4.1. Chain Pharmacy
11.4.2. Independent Pharmacy
12. Pain Management Therapeutics Market, by End User
12.1. Introduction
12.2. Ambulatory Surgical Centers
12.3. Home Care Settings
12.3.1. Hospice Care
12.3.2. Patient Home
12.4. Hospitals
12.4.1. Private Hospitals
12.4.2. Public Hospitals
13. Americas Pain Management Therapeutics Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Pain Management Therapeutics Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Pain Management Therapeutics Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Johnson & Johnson
16.3.2. Pfizer Inc.
16.3.3. Novartis AG
16.3.4. Bayer AG
16.3.5. GlaxoSmithKline plc
16.3.6. Sanofi S.A.
16.3.7. Teva Pharmaceutical Industries Ltd.
16.3.8. Endo International plc
16.3.9. Mallinckrodt plc
16.3.10. AstraZeneca plc
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. PAIN MANAGEMENT THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. PAIN MANAGEMENT THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. PAIN MANAGEMENT THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. PAIN MANAGEMENT THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. PAIN MANAGEMENT THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. PAIN MANAGEMENT THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ADJUVANT ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COX-2 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRADITIONAL NSAIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY STRONG OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY WEAK OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CANCER PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOW BACK PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC CHRONIC PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INFLAMMATORY PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPICE CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PATIENT HOME, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 86. CANADA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 87. CANADA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2030 (USD MILLION)
TABLE 88. CANADA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
TABLE 89. CANADA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 90. CANADA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 91. CANADA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 92. CANADA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 93. CANADA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 94. CANADA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. CANADA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 96. CANADA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. CANADA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 98. CANADA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 99. MEXICO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 100. MEXICO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2030 (USD MILLION)
TABLE 101. MEXICO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
TABLE 102. MEXICO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 103. MEXICO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 104. MEXICO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 105. MEXICO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 106. MEXICO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 107. MEXICO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 108. MEXICO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 109. MEXICO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. MEXICO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 111. MEXICO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2030 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 152. UNITED KINGDOM PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2030 (USD MILLION)
TABLE 154. UNITED KINGDOM PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 156. UNITED KINGDOM PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 158. UNITED KINGDOM PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 160. UNITED KINGDOM PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 161. UNITED KINGDOM PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 162. UNITED KINGDOM PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 164. UNITED KINGDOM PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 165. GERMANY PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 166. GERMANY PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2030 (USD MILLION)
TABLE 167. GERMANY PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
TABLE 168. GERMANY PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 169. GERMANY PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 170. GERMANY PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 171. GERMANY PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 172. GERMANY PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 173. GERMANY PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. GERMANY PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 175. GERMANY PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 176. GERMANY PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 177. GERMANY PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 178. FRANCE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 179. FRANCE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2030 (USD MILLION)
TABLE 180. FRANCE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
TABLE 181. FRANCE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 182. FRANCE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 183. FRANCE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 184. FRANCE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 185. FRANCE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 186. FRANCE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 187. FRANCE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 188. FRANCE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. FRANCE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 190. FRANCE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 199. RUSSIA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 200. RUSSIA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 201. RUSSIA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 202. RUSSIA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 203. RUSSIA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 204. ITALY PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 205. ITALY PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2030 (USD MILLION)
TABLE 206. ITALY PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
TABLE 207. ITALY PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 208. ITALY PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 209. ITALY PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 210. ITALY PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 211. ITALY PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 212. ITALY PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 213. ITALY PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 214. ITALY PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 215. ITALY PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 216. ITALY PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 217. SPAIN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 218. SPAIN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2030 (USD MILLION)
TABLE 219. SPAIN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
TABLE 220. SPAIN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 221. SPAIN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 222. SPAIN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 223. SPAIN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 224. SPAIN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 225. SPAIN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 226. SPAIN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 227. SPAIN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 228. SPAIN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 229. SPAIN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 235. UNITED ARAB EMIRATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 236. UNITED ARAB EMIRATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 237. UNITED ARAB EMIRATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 238. UNITED ARAB EMIRATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 239. UNITED ARAB EMIRATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 240. UNITED ARAB EMIRATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 241. UNITED ARAB EMIRATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 242. UNITED ARAB EMIRATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 244. SAUDI ARABIA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2030 (USD MILLION)
TABLE 245. SAUDI ARABIA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
TABLE 246. SAUDI ARABIA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 247. SAUDI ARABIA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 248. SAUDI ARABIA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 249. SAUDI ARABIA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 250. SAUDI ARABIA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 251. SAUDI ARABIA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 252. SAUDI ARABIA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 253. SAUDI ARABIA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 254. SAUDI ARABIA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 255. SAUDI ARABIA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 256. SOUTH AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 257. SOUTH AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2030 (USD MILLION)
TABLE 258. SOUTH AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
TABLE 259. SOUTH AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 260. SOUTH AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 261. SOUTH AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 262. SOUTH AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 263. SOUTH AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 264. SOUTH AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 265. SOUTH AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 266. SOUTH AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 267. SOUTH AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 268. SOUTH AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 269. DENMARK PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 270. DENMARK PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2030 (USD MILLION)
TABLE 271. DENMARK PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
TABLE 272. DENMARK PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 273. DENMARK PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 274. DENMARK PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 275. DENMARK PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 276. DENMARK PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 277. DENMARK PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 278. DENMARK PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 279. DENMARK PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 280. DENMARK PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 281. DENMARK PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 282. NETHERLANDS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 283. NETHERLANDS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2030 (USD MILLION)
TABLE 284. NETHERLANDS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
TABLE 285. NETHERLANDS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 286. NETHERLANDS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 287. NETHERLANDS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 288. NETHERLANDS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 289. NETHERLANDS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 290. NETHERLANDS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 291. NETHERLANDS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 292. NETHERLANDS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 293. NETHERLANDS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 294. NETHERLANDS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 295. QATAR PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 296. QATAR PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2030 (USD MILLION)
TABLE 297. QATAR PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD MILLION)
TABLE 298. QATAR PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 299. QATAR PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 300. QATAR PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 301. QATAR PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 302. QATAR PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2030 (USD MILLION)
TABLE 303. QATAR PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHA

Companies Mentioned

The companies profiled in this Pain Management Therapeutics market report include:
  • Johnson & Johnson
  • Pfizer Inc.
  • Novartis AG
  • Bayer AG
  • GlaxoSmithKline plc
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Endo International plc
  • Mallinckrodt plc
  • AstraZeneca plc

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages182
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 90.67 Billion
Forecasted Market Value ( USD ) by 2030 $ 114.41 Billion
Compound Annual Growth Rate4.7%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Cancer Pain Management Market by Drug Class, Route Of Administration, Distribution Channel, End User, Application - Global Forecast to 2030 - Product Image

Cancer Pain Management Market by Drug Class, Route Of Administration, Distribution Channel, End User, Application - Global Forecast to 2030

  • Report
  • 189 Pages
  • Global
From
Post Operative Pain Management - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

Post Operative Pain Management - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 111 Pages
  • Global
From
Pain Management Drugs Market Report by Drug Class, Indication, Distribution Channel, and Region 2025-2033 - Product Image

Pain Management Drugs Market Report by Drug Class, Indication, Distribution Channel, and Region 2025-2033

  • Report
  • 149 Pages
  • Global
From
Post operative pain management - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Post operative pain management - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Advanced Cancer Pain Management - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Advanced Cancer Pain Management - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From

About the Pain Management Market

The Pain Management market within the context of Analgesics is a large and diverse field. It includes a variety of products and services designed to reduce or eliminate pain. These products and services range from over-the-counter medications to prescription drugs, physical therapy, and alternative treatments. Analgesics are a type of medication used to reduce or eliminate pain. They can be divided into two main categories: non-opioid analgesics, such as ibuprofen and acetaminophen, and opioid analgesics, such as morphine and oxycodone. Non-opioid analgesics are generally considered to be safer and more effective than opioid analgesics, but they are not as effective at treating severe pain. The Pain Management market is highly competitive, with many companies offering a variety of products and services. Some of the major players in the market include Pfizer, Johnson & Johnson, GlaxoSmithKline, Merck, Novartis, and Eli Lilly. Other companies in the market include Teva Pharmaceuticals, Mylan, and Endo Pharmaceuticals. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.